On March 26, 2024, the kick-off meeting of the metabolically enhanced CD19 CAR-T cell (Meta10-19 injection) IIT clinical study project, developed by Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), was held in the Hubin Campus of the Children's Hospital Affiliated to Zhejiang University School of Medicine (hereinafter referred to as "Zhejiang University Children's Hospital").

Lausanne, April 21, 2024 - Leman Biotech, a clinical-stage biotechnology company focusing on the development, production, and commercialization of innovative metabolic immunotherapies, will deliver an oral presentation at the 27^th American Society of Gene and Cell Therapy (ASGCT) annual meeting, to be held in Baltimore, MD, from May 7th to 11th, 2024. We will present UPDATED clinical results from our first-in-human investigator-initiated clinical trials for Metabolically Armed CD19 CAR-T Cell therapy for relapsed or refractory B cell hematological malignancies. Our Associate Director of R&D Dr. Jingjing Ren will deliver the presentation.

Lausanne, March 27, 2024 - Leman Biotech, a clinical-stage biotechnology company focusing on the development, production, and commercialization of innovative metabolic immunotherapies, will deliver an oral presentation at the American Association of Cancer Research (AACR) annual meeting, to be held in San Diego, CA, from April 5th to 10th, 2024. We will present clinical results from our first-in-human investigator-initiated clinical trials for Metabolically Armed CD19 CAR-T Cell therapy for relapsed or refractory B cell hematological malignancies. Our Co-Founder and President Prof. Li Tang and Translational Research Director of our Swiss Research Center Dr. Karthik Sathiyanadan will attend the meeting. Our Associate Director of R&D Dr. Jingjing Ren will deliver the presentation.

On January 2, 2024, Prof. Li Tang and Dr. Yugang Guo, co-founders of Leman Biotech, published a paper in the top international academic journal Nature Biotechnology (IF=68), titled "IL-10-expressing CAR-T cells resist dysfunction and mediate durable clearance of solid tumors and metastases". The paper comprehensively reveals the preclinical research results of metabolically enhanced Meta 10 CAR-T therapy for solid tumors. The relevant findings suggest that Meta 10 CAR-T has enormous potential for curing solid tumors.

Leman Biotech was invited to participate in the Swiss Group for Clinical Cancer Research (SAKK)'s Cellular Therapies Workshop held as part of the 6th annual Swiss Oncology and Hematology Congress.Leman Biotech was one of four Top Swiss companies invited to present in the sessions: "Engineered Cells" and "Manufacturing Devices & Technology," showcasing their cutting-edge technologies and advancements in cell therapy development. Prof. Dr. George Coukos had previously given a welcome note and opened the session.

Recently, the "15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference," also known as the Qisihui Conference, was held in Hangzhou. During the conference, the "Top 100 Best in China Pharmaceutical Innovation Value Discovery" for the year 2022-2023 was announced. Leman Biotech was successfully selected for its project "AI Empowered Metabolically Enhanced Immunotherapy."

On October 22nd, the National Cancer Centre Singapore (NCCS) hosted a Charity GALA Dinner with the theme "Celebrating the past, Building hope for the future." Leman Biotech, as a representative of emerging enterprises in cancer immunotherapy, was invited by NCCS. Dr. Dudu Tong, the R&D Director, attended the grand event on behalf of the company and received a cordial reception from prominent figures, including Mr. Heng Swee Keat, the Deputy Prime Minister of Singapore.